Cargando…
Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis
Psoriasis is a chronic inflammatory disease of the skin and joints. More recent data emphasize an association with dysregulated glucose and fatty acid metabolism, obesity, elevated blood pressure and cardiac disease, summarized as metabolic syndrome. TNF-α and IL-17, central players in the pathogene...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517119/ https://www.ncbi.nlm.nih.gov/pubmed/34660638 http://dx.doi.org/10.3389/fmed.2021.730164 |
_version_ | 1784583943172915200 |
---|---|
author | Mentzel, Julia Kynast, Tabea Kohlmann, Johannes Kirsten, Holger Blüher, Matthias Simon, Jan C. Kunz, Manfred Saalbach, Anja |
author_facet | Mentzel, Julia Kynast, Tabea Kohlmann, Johannes Kirsten, Holger Blüher, Matthias Simon, Jan C. Kunz, Manfred Saalbach, Anja |
author_sort | Mentzel, Julia |
collection | PubMed |
description | Psoriasis is a chronic inflammatory disease of the skin and joints. More recent data emphasize an association with dysregulated glucose and fatty acid metabolism, obesity, elevated blood pressure and cardiac disease, summarized as metabolic syndrome. TNF-α and IL-17, central players in the pathogenesis of psoriasis, are known to impair bone formation. Therefore, the relation between psoriasis and bone metabolism parameters was investigated. Two serum markers of either bone formation—N-terminal propeptide of type I procollagen (P1NP) or bone resorption—C-terminal telopeptide of type I collagen (CTX-I)—were analyzed in a cohort of patients with psoriasis vulgaris. In patients with psoriasis, P1NP serum levels were reduced compared to gender-, age-, and body mass index-matched healthy controls. CTX-I levels were indistinguishable between patients with psoriasis and controls. Consistently, induction of psoriasis-like skin inflammation in mice decreases bone volume and activity of osteoblasts. Moreover, efficient anti-psoriatic treatment improved psoriasis severity, but did not reverse decreased P1NP level suggesting that independent of efficient skin treatment psoriasis did affect bone metabolism and might favor the development of osteoporosis. Taken together, evidence is provided that bone metabolism might be affected by psoriatic inflammation, which may have consequences for future patient counseling and disease monitoring. |
format | Online Article Text |
id | pubmed-8517119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85171192021-10-16 Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis Mentzel, Julia Kynast, Tabea Kohlmann, Johannes Kirsten, Holger Blüher, Matthias Simon, Jan C. Kunz, Manfred Saalbach, Anja Front Med (Lausanne) Medicine Psoriasis is a chronic inflammatory disease of the skin and joints. More recent data emphasize an association with dysregulated glucose and fatty acid metabolism, obesity, elevated blood pressure and cardiac disease, summarized as metabolic syndrome. TNF-α and IL-17, central players in the pathogenesis of psoriasis, are known to impair bone formation. Therefore, the relation between psoriasis and bone metabolism parameters was investigated. Two serum markers of either bone formation—N-terminal propeptide of type I procollagen (P1NP) or bone resorption—C-terminal telopeptide of type I collagen (CTX-I)—were analyzed in a cohort of patients with psoriasis vulgaris. In patients with psoriasis, P1NP serum levels were reduced compared to gender-, age-, and body mass index-matched healthy controls. CTX-I levels were indistinguishable between patients with psoriasis and controls. Consistently, induction of psoriasis-like skin inflammation in mice decreases bone volume and activity of osteoblasts. Moreover, efficient anti-psoriatic treatment improved psoriasis severity, but did not reverse decreased P1NP level suggesting that independent of efficient skin treatment psoriasis did affect bone metabolism and might favor the development of osteoporosis. Taken together, evidence is provided that bone metabolism might be affected by psoriatic inflammation, which may have consequences for future patient counseling and disease monitoring. Frontiers Media S.A. 2021-10-01 /pmc/articles/PMC8517119/ /pubmed/34660638 http://dx.doi.org/10.3389/fmed.2021.730164 Text en Copyright © 2021 Mentzel, Kynast, Kohlmann, Kirsten, Blüher, Simon, Kunz and Saalbach. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Mentzel, Julia Kynast, Tabea Kohlmann, Johannes Kirsten, Holger Blüher, Matthias Simon, Jan C. Kunz, Manfred Saalbach, Anja Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis |
title | Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis |
title_full | Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis |
title_fullStr | Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis |
title_full_unstemmed | Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis |
title_short | Reduced Serum Levels of Bone Formation Marker P1NP in Psoriasis |
title_sort | reduced serum levels of bone formation marker p1np in psoriasis |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517119/ https://www.ncbi.nlm.nih.gov/pubmed/34660638 http://dx.doi.org/10.3389/fmed.2021.730164 |
work_keys_str_mv | AT mentzeljulia reducedserumlevelsofboneformationmarkerp1npinpsoriasis AT kynasttabea reducedserumlevelsofboneformationmarkerp1npinpsoriasis AT kohlmannjohannes reducedserumlevelsofboneformationmarkerp1npinpsoriasis AT kirstenholger reducedserumlevelsofboneformationmarkerp1npinpsoriasis AT bluhermatthias reducedserumlevelsofboneformationmarkerp1npinpsoriasis AT simonjanc reducedserumlevelsofboneformationmarkerp1npinpsoriasis AT kunzmanfred reducedserumlevelsofboneformationmarkerp1npinpsoriasis AT saalbachanja reducedserumlevelsofboneformationmarkerp1npinpsoriasis |